Technical Analysis for MCRB - Seres Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical MCRB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Doji - Bullish? | Reversal | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 17 | Wide Bands | Range Expansion | 1.06% |
| Jan 17 | Overbought Stochastic | Strength | 1.06% |
| Jan 16 | Weak + Overbought | Other | -4.03% |
| Jan 16 | Outside Day | Range Expansion | -4.03% |
| Jan 16 | Wide Bands | Range Expansion | -4.03% |
| Jan 16 | Overbought Stochastic | Strength | -4.03% |
| Jan 15 | NR7 | Range Contraction | -7.90% |
| Jan 15 | Weak + Overbought | Other | -7.90% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-14
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MCRB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 11.345 |
| 52 Week Low | 4.42 |
| Average Volume | 98,699 |
| 200-Day Moving Average | 7.6296 |
| 50-Day Moving Average | 6.8034 |
| 20-Day Moving Average | 5.416 |
| 10-Day Moving Average | 5.923 |
| Average True Range | 0.4351 |
| ADX | 22.34 |
| +DI | 19.8726 |
| -DI | 22.746 |
| Chandelier Exit (Long, 3 ATRs ) | 5.1347 |
| Chandelier Exit (Short, 3 ATRs ) | 5.7253 |
| Upper Bollinger Band | 6.5821 |
| Lower Bollinger Band | 4.2499 |
| Percent B (%b) | 0.63 |
| BandWidth | 43.0613 |
| MACD Line | -0.1573 |
| MACD Signal Line | -0.2819 |
| MACD Histogram | 0.1246 |
| Fundamentals | Value |
|---|---|
| Market Cap | 231.32 Million |
| Num Shares | 40.5 Million |
| EPS | -2.42 |
| Price-to-Earnings (P/E) Ratio | -2.36 |
| Price-to-Sales | 17.96 |
| Price-to-Book | 4.50 |
| PEG Ratio | 0.03 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.18 | ||||
| Resistance 3 (R3) | 6.17 | 6.00 | 6.10 | ||
| Resistance 2 (R2) | 6.00 | 5.88 | 6.01 | 6.07 | |
| Resistance 1 (R1) | 5.86 | 5.81 | 5.93 | 5.87 | 6.05 |
| Pivot Point | 5.69 | 5.69 | 5.73 | 5.70 | 5.69 |
| Support 1 (S1) | 5.55 | 5.57 | 5.62 | 5.56 | 5.37 |
| Support 2 (S2) | 5.38 | 5.50 | 5.39 | 5.35 | |
| Support 3 (S3) | 5.24 | 5.38 | 5.32 | ||
| Support 4 (S4) | 5.25 |
